Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | NEK2 | P51955 | 5/20 | 0.53 |
| ▸ | PRKDC | P78527 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | NOS1 | P29475 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6696565 | 0.94 | ATR (0.57) | ATRKMT2ANEK2PRKDCNPC1 | |
| SCHEMBL6697532 | 0.94 | ATR (0.57) | ATRKMT2ANEK2PRKDCNPC1 | |
| SCHEMBL934180 | 0.82 | ATR (0.51) | ATRKMT2ANEK2PRKDCNPC1 | |
| SCHEMBL5959065 | 0.81 | NPC1 (0.54) | ATRNEK2NPC1RAB9AALDH1A1 | |
| SCHEMBL11907360 | 0.80 | ATR (0.70) | ATRNEK2PRKDC | |
| SCHEMBL935105 | 0.80 | MAPT (0.50) | ATRKMT2ANEK2PRKDCNPC1 | |
| SCHEMBL13067556 | 0.80 | HEXA (0.55) | ATRKMT2ANEK2PRKDCNPC1 | |
| SCHEMBL2500547 | 0.79 | KCNH2 (0.43) | ATRNEK2PRKDC | |
| SCHEMBL6700778 | 0.78 | KMT2A (0.54) | KMT2ANPC1RAB9AMAPK1ALDH1A1 | |
| SCHEMBL6696482 | 0.77 | PIK3CG (0.55) | ATRNEK2PRKDCMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040034225-A1 | Aryl-substituted n, n-heterocyclic compounds, method for their preparationand their use in therapeutics and diagnostics | UNIVERSITY CATHOLIQUE DE LOUVAIN (BE) | 2004-02-19 | — | — | US | claimed |
| EP-1292580-A1 | PYRAZINE AND IMIDAZOPYRAZINE DERIVATIVES AS ANTIOXIDANTS | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 2003-03-19 | — | — | EP | claimed |
| WO-2001087853-A1 | ARYL-SUBSTITUTED N,N-HETEROCYCLIC COMPOUNDS, METHOD FOR THEIR PREPARATION AND THEIR USE IN THERAPEUTICS AND DIAGNOSTICS | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 2001-11-22 | — | — | WO | claimed |
| US-20040034225-A1 | Aryl-substituted n, n-heterocyclic compounds, method for their preparationand their use in therapeutics and diagnostics | UNIVERSITY CATHOLIQUE DE LOUVAIN (BE) | 2004-02-19 | — | — | US | disclosed |
| US-20040034225-A1 | Aryl-substituted n, n-heterocyclic compounds, method for their preparationand their use in therapeutics and diagnostics | UNIVERSITY CATHOLIQUE DE LOUVAIN (BE) | 2004-02-19 | — | — | US | disclosed |
| EP-1292580-A1 | PYRAZINE AND IMIDAZOPYRAZINE DERIVATIVES AS ANTIOXIDANTS | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 2003-03-19 | — | — | EP | disclosed |
| EP-1292580-A1 | PYRAZINE AND IMIDAZOPYRAZINE DERIVATIVES AS ANTIOXIDANTS | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 2003-03-19 | — | — | EP | disclosed |
| WO-2001087853-A1 | ARYL-SUBSTITUTED N,N-HETEROCYCLIC COMPOUNDS, METHOD FOR THEIR PREPARATION AND THEIR USE IN THERAPEUTICS AND DIAGNOSTICS | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 2001-11-22 | — | — | WO | disclosed |
| WO-2001087853-A1 | ARYL-SUBSTITUTED N,N-HETEROCYCLIC COMPOUNDS, METHOD FOR THEIR PREPARATION AND THEIR USE IN THERAPEUTICS AND DIAGNOSTICS | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034225-A1 | Aryl-substituted n, n-heterocyclic compounds, method for their preparationand their use in therapeutics and diagnostics | NOX5, NOX4, CD22 | ATR 4853/4885KMT2A 4602/4885NEK2 1678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.